FLEX Vessel Prep Shows Strong 12-Month Outcomes
LONDON, April 23, 2026 In a significant advancement for vascular access treatment, FLEX Vascular has announced 12-month real-world outcomes...
clinical outcomes
Advertisement
GlycoNex Secures PMDA Nod for GNX1021 Phase 1 Trial
NEW TAIPEI CITY, TAIWAN, April 14, 2026 GlycoNex, Inc. has received approval from Japan’s Pharmaceuticals and Medical Devices Agency...
Revolution Medicines Reports Phase 3 Survival Gain PDAC
REDWOOD CITY, CALIFORNIA, USA, April 13, 2026 Revolution Medicines has announced positive topline results from its pivotal Phase 3...
Neurocrine Shows INGREZZA Persistence Edge in TD Study
SAN DIEGO, USA, April 14, 2026 Neurocrine Biosciences has presented new real-world evidence (RWE) demonstrating that patients treated with...
Eisai and Biogen Report Strong LEQEMBI Long-Term Adherence Data
Copenhagen, Denmark | March 23, 2026 New real-world evidence presented at the AD/PD™ 2026 conference highlights that LEQEMBI® (lecanemab-irmb)...
Advertisements
MIPLYFFA Real-World Data Strengthen NPC Treatment Impact
CELEBRATION, Fla., Feb. 4, 2026 —Zevra Therapeutics announced the presentation of positive new real-world data on MIPLYFFA® (arimoclomol) in...
Amgen’s VESALIUS-CV Trial Shows Success in Heart Disease Prevention
THOUSAND OAKS, Calif., Oct. 1, 2025 — Amgen announced that its landmark VESALIUS-CV Phase 3 trial met primary endpoints...
Larimar’s Nomlabofusp Shows Long-Term Promise in Friedreich’s Ataxia
Bala Cynwyd, Pa., September 29, 2025: Larimar Therapeutics announced positive new data from an ongoing long-term open-label study of...
High ESA Failure Rates Revealed in Lower-Risk MDS Real-World Study
September 22, 2025 — Florida, USA — A recent real-world retrospective study of 359 adult patients with lower-risk myelodysplastic...
Advertisement
